Author

Jill L. Buss

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Andrea LagansoniD· 2 shared Ann‐Kathrin EisfeldiD· 2 shared Sanam LoghaviiD· 2 shared Adrienne Heyrosa· 1 shared Alan H. ShihiD· 1 shared Alice S. MimsiD· 1 shared Andrew J. CarrolliD· 1 shared Andrew R. StiffiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrea LagansonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia

Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrózek, Mark J. Routbort, Keyur Pravinchandra Patel, Christopher James Walker, Jill L. Buss, Andrew R. Stiff, Andrea Laganson, Courtney Denton Dinardo, Naval Guastad Daver, Tapan Mahendra Kadia, Farhad Ravandi, , Linde A. Miles

This study identifies BRAF mutations in AML, showing poor outcomes and unique co-mutation patterns, suggesting potential targeted therapies.

Leukemia · Jun 15, 2026Peer-reviewedCancer Biology

Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma

Bettina Nadorp, Audrey Lasry, Sanam Loghavi, Ravi Patel, Hager M. Mansour, Benjamin Kelly, Christopher J. Walker, Jill L. Buss, Isaiah Boateng, Wafa Al-Santli, Zoe B. Ciantra, Rebecca J. Austin, Adrienne Heyrosa, Helee Desai, Andrea Laganson, , Ann‐Kathrin Eisfeld

This study characterizes myeloid sarcoma through multi-omic profiling, identifies RAS pathway activation as a hallmark, and shows RAS inhibition reduces tumor burden in mouse models.

bioRxiv · Dec 5, 2025 · PreprintCancer Biology